A recent study by EpiVax and Cubrc, in partnership with the U.S. Food and Drug Administration (FDA), has made it easier to safely create generic versions of the osteoporosis drug teriparatide. This drug, which is a synthetic version of a natural hormone, helps strengthen bones in people with osteoporosis. The research focused on identifying and controlling small impurities in generic peptide drugs that could cause unwanted immune system reactions. Generic drugs are typically more affordable, so making them safer to use is important for patients who rely on them. Teriparatide was specifically mentioned in recent FDA guidelines that recommend checking for immune risks in synthetic generic drugs submitted for approval. Using advanced computer programs and lab tests, the researchers found several impurities in generic teriparatide that could be more likely to trigger immune responses than the original drug. They also discovered a part of the teriparatide molecule that might help reduce immune reactions, but this protective effect could be lost if the impurities change the drug’s structure. The study’s authors emphasized that while the active ingredient in generic drugs must be the same as the original, manufacturing processes can sometimes introduce small changes that create new immune triggers. Dr. Vibha Jawa, Chief Scientific Officer at EpiVax, explained that combining computer analysis with real-world lab testing is a powerful way to better understand and reduce the risk of immune reactions in generic peptide drugs. She added that the findings provide a clear method for drug developers to follow the FDA’s guidelines on checking for impurities and improve the safety of these medications. The research was published in the journal Frontiers in Immunology.